Search results (126)
« Back to PublicationsEpigenetic modulation of stromal cell states underpins pathological tissue niches in Crohn's disease.
Koplev S. et al, (2026), Nat Immunol
ATF4-mediated stress response as a therapeutic vulnerability in chordoma.
Cottone L. et al, (2026), Mol Oncol, 20, 1008 - 1021
DNA demethylation-mediated downregulation of MNX1 in acute myeloid leukemia.
Kelekçi S. et al, (2025), Leukemia, 39, 2270 - 2274
Epigenetic drug screening identifies enzyme inhibitors A-196 and TMP-269 as novel regulators of sprouting angiogenesis.
Beter M. et al, (2025), Sci Rep, 15
ATF4-Mediated Metabolic Stress Response as a Therapeutic Vulnerability in Chordoma
Cottone L. et al, (2025)
The pRb/RBL2-E2F1/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry/exit by paracrine mechanisms.
Chang C-H. et al, (2024), Nat Commun, 15
BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma.
Feng Y. et al, (2024), Gastroenterology, 166, 139 - 154
Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases.
Pagnamenta AT. et al, (2023), Genome Med, 15
HSD3B1 is an oxysterol 3β-hydroxysteroid dehydrogenase in human placenta.
Dickson A. et al, (2023), Open Biol, 13
Discovery of a Potent and Selective Naphthyridine-Based Chemical Probe for Casein Kinase 2.
Davis-Gilbert ZW. et al, (2023), ACS Med Chem Lett, 14, 432 - 441
BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma.
Feng Y. et al, (2023), bioRxiv
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K. et al, (2023), Blood Cancer J, 13
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K. et al, (2023), Blood Cancer J, 13
BRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming.
Sevinç K. et al, (2022), Stem Cell Reports, 17, 2629 - 2642